Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of 10-valent pneumococcal conjugate vaccine co-administered with DTPa in healthy Japanese infants
2011-003710-16Phase 3
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of 10-valent pneumococcal conjugate vaccine and diphtheria toxoid + tetanus toxoid + acellular pertussis in pneumococcal disease, invasive pneumococcal disease (IPD) and acute otitis media (AOM) (2 arms), sponsored by GSK. Primary endpoint: Primary immunogenicity endpoint.
02
Drugs
10-valent pneumococcal conjugate vaccinediphtheria toxoid + tetanus toxoid + acellular pertussis
03
Conditions
pneumococcal diseaseinvasive pneumococcal disease (IPD)acute otitis media (AOM)
Beyond the preview
Go deeper on 2011-003710-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003710-16.